567 related articles for article (PubMed ID: 27586020)
41. Pyrrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1).
Schmitt SM; Stefan K; Wiese M
Biochim Biophys Acta Biomembr; 2017 Jan; 1859(1):69-79. PubMed ID: 27810353
[TBL] [Abstract][Full Text] [Related]
42. Fluorescence-Based Transport Assays Revisited in a Human Renal Proximal Tubule Cell Line.
Caetano-Pinto P; Janssen MJ; Gijzen L; Verscheijden L; Wilmer MJ; Masereeuw R
Mol Pharm; 2016 Mar; 13(3):933-44. PubMed ID: 26871298
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of Breast Cancer Resistance Protein and Multidrug Resistance Associated Protein 2 by Natural Compounds and Their Derivatives.
Sjöstedt N; Holvikari K; Tammela P; Kidron H
Mol Pharm; 2017 Jan; 14(1):135-146. PubMed ID: 28043125
[TBL] [Abstract][Full Text] [Related]
44. Formation and efflux of ATP-binding cassette transporter substrate 2,4-dinitrophenyl-S-glutathione from cultured human term placental villous tissue fragments.
Vaidya SS; Walsh SW; Gerk PM
Mol Pharm; 2009; 6(6):1689-702. PubMed ID: 19397308
[TBL] [Abstract][Full Text] [Related]
45. Therapy-relevant aberrant expression of MRP3 and BCRP mRNA in TCC-/SCC-bladder cancer tissue of untreated patients.
Rady M; Mostageer M; Rohde J; Zaghloul A; Knüchel-Clarke R; Saad S; Attia D; Mahran L; Spahn-Langguth H
Oncol Rep; 2017 Jul; 38(1):551-560. PubMed ID: 28586062
[TBL] [Abstract][Full Text] [Related]
46. Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.
Te Brake LH; Russel FG; van den Heuvel JJ; de Knegt GJ; de Steenwinkel JE; Burger DM; Aarnoutse RE; Koenderink JB
Tuberculosis (Edinb); 2016 Jan; 96():150-7. PubMed ID: 26682943
[TBL] [Abstract][Full Text] [Related]
47. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
48. Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Determine the Disposition of Esculetin-7-O-Glucuronide and 4-Methylesculetin-7-O-Glucuronide.
Li Y; Song W; Ou X; Luo G; Xie Y; Sun R; Wang Y; Qi X; Hu M; Liu Z; Zhu L
Drug Metab Dispos; 2019 Mar; 47(3):203-214. PubMed ID: 30602435
[TBL] [Abstract][Full Text] [Related]
49. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Pedersen JM; Matsson P; Bergström CA; Norinder U; Hoogstraate J; Artursson P
J Med Chem; 2008 Jun; 51(11):3275-87. PubMed ID: 18457386
[TBL] [Abstract][Full Text] [Related]
50. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
51. Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1.
Qi X; Wagenaar E; Xu W; Huang K; Schinkel AH
Toxicol Appl Pharmacol; 2017 Aug; 329():18-25. PubMed ID: 28532671
[TBL] [Abstract][Full Text] [Related]
52. Cremophor EL-based nanoemulsion enhances transcellular permeation of emodin through glucuronidation reduction in UGT1A1-overexpressing MDCKII cells.
Zhang T; Dong D; Lu D; Wang S; Wu B
Int J Pharm; 2016 Mar; 501(1-2):190-8. PubMed ID: 26850314
[TBL] [Abstract][Full Text] [Related]
53. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides.
Sesink AL; Arts IC; de Boer VC; Breedveld P; Schellens JH; Hollman PC; Russel FG
Mol Pharmacol; 2005 Jun; 67(6):1999-2006. PubMed ID: 15749994
[TBL] [Abstract][Full Text] [Related]
54. Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids.
Hariharan S; Gunda S; Mishra GP; Pal D; Mitra AK
Pharm Res; 2009 May; 26(5):1270-82. PubMed ID: 18958406
[TBL] [Abstract][Full Text] [Related]
55. Characterization of chrysin glucuronidation in UGT1A1-overexpressing HeLa cells: elucidating the transporters responsible for efflux of glucuronide.
Quan E; Wang H; Dong D; Zhang X; Wu B
Drug Metab Dispos; 2015 Apr; 43(4):433-43. PubMed ID: 25595598
[TBL] [Abstract][Full Text] [Related]
56. Efflux transport of nicotine, cotinine and trans-3'-hydroxycotinine glucuronides by human hepatic transporters.
Järvinen E; Sjöstedt N; Koenderink JB; Kidron H; Finel M
Basic Clin Pharmacol Toxicol; 2019 Dec; 125(6):490-498. PubMed ID: 31237077
[TBL] [Abstract][Full Text] [Related]
57. Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP.
Lempers VJ; van den Heuvel JJ; Russel FG; Aarnoutse RE; Burger DM; Brüggemann RJ; Koenderink JB
Antimicrob Agents Chemother; 2016 Jun; 60(6):3372-9. PubMed ID: 27001813
[TBL] [Abstract][Full Text] [Related]
58. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
Dahan A; Sabit H; Amidon GL
AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
[TBL] [Abstract][Full Text] [Related]
59. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.
An G; Gallegos J; Morris ME
Drug Metab Dispos; 2011 Mar; 39(3):426-32. PubMed ID: 21139040
[TBL] [Abstract][Full Text] [Related]
60. Substrate and method dependent inhibition of three ABC-transporters (MDR1, BCRP, and MRP2).
Pedersen JM; Khan EK; Bergström CAS; Palm J; Hoogstraate J; Artursson P
Eur J Pharm Sci; 2017 May; 103():70-76. PubMed ID: 28263911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
